Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Liabilities from Discontinued Operations (2020)

Serina Therapeutics (SER) has disclosed Liabilities from Discontinued Operations for 1 consecutive years, with 2431000.0 as the latest value for Q4 2020.

  • Quarterly Liabilities from Discontinued Operations changed N/A to 2431000.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was 2431000.0 through Dec 2020, changed N/A year-over-year, with the annual reading at 2431000.0 for FY2020, N/A changed from the prior year.
  • Liabilities from Discontinued Operations hit 2431000.0 in Q4 2020 for Serina Therapeutics.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 2431000.0 in Q4 2020 to a low of 2431000.0 in Q4 2020.